Affiliation:
1. Department of Pulmonology, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania
2. Laboratory of Pulmonology, Department of Pulmonology, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania
Abstract
Anti-interleukin (IL) 5 is an effective treatment modality for inhibiting eosinophilic inflammation in patients with T2-high severe asthma. The aim of this study was to determine the clinical efficacy and serum levels of type 2 inflammatory mediators during 24 weeks of mepolizumab treatment in patients with T2-high severe asthma. Eighteen patients with T2-high severe asthma were enrolled in this study. All patients received 100 mg of mepolizumab subcutaneously every 4 weeks and were retested at 4, 12, and 24 weeks. A clinical examination, asthma control test (ACT), and spirometry were performed; fractional exhaled nitric oxide (FeNO) levels were evaluated; and blood samples were drawn at every visit. Type 2 inflammation mediator levels were measured using enzyme-linked immunosorbent assay (ELISA). The blood eosinophil level significantly decreased, the ACT score and FEV1 increased after 4 weeks of mepolizumab treatment with the same tendency after 12 and 24 weeks (p < 0.05), and the FeNO level did not change (p > 0.05). A total of 27.8% of patients reached clinical remission criteria after 24 weeks of mepolizumab treatment. IL-33 and eotaxin significantly increased (p < 0.05) while IL-5, IL-13, thymic stromal lymphopoietin (TSLP), soluble IL-5 receptor subunit alpha (sIL-5Rα), and soluble high-affinity immunoglobulin E receptor (sFcεRI) decreased, with the same tendency after 12 and 24 weeks (p < 0.05). The serum levels of immunoglobulin (Ig) E and IL-4 and IL-25 levels did not change during mepolizumab treatment compared to baseline (p > 0.05). In conclusion, treatment with mepolizumab over 24 weeks improved lung function and asthma control in T2-high severe asthma patients, with nearly one-third achieving clinical remission criteria, and affected the balance of type 2 inflammatory mediators.
Funder
This study was funded by The Future Biomedicine Foundation (project number 2017) and the Science Foundation of the Lithuanian University of Health Sciences.
Reference50 articles.
1. Hussain, M., and Liu, G. (2024). Eosinophilic Asthma: Pathophysiology and Therapeutic Horizons. Cells, 13.
2. Eosinophil apoptosis as a therapeutic target in allergic asthma;Ilmarinen;Basic. Clin. Pharmacol. Toxicol.,2014
3. Role of IL-25, IL-33, and TSLP in triggering united airway diseases toward type 2 inflammation;Hong;Allergy,2020
4. Pelaia, C., Paoletti, G., Puggioni, F., Racca, F., Pelaia, G., Canonica, G.W., and Heffler, E. (2019). Interleukin-5 in the Pathophysiology of Severe Asthma. Front. Physiol., 10.
5. Type 2 inflammation in asthma—present in most, absent in many;Fahy;Nat. Rev. Immunol.,2015